{"id":"baloxavir-marboxil-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL4297503","moleculeType":"Small molecule","molecularWeight":"571.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Baloxavir marboxil is a prodrug that is converted to its active form, baloxavir, which selectively inhibits the polymerase acidic (PA) protein endonuclease of influenza viruses. This enzyme is essential for viral mRNA synthesis, as it cleaves host pre-mRNA to generate primers for viral transcription. By blocking this mechanism, the drug prevents the virus from synthesizing its own mRNA and replicating.","oneSentence":"Baloxavir marboxil inhibits the influenza virus endonuclease, blocking viral cap-dependent transcription and preventing viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:28.638Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute uncomplicated influenza (treatment)"},{"name":"Influenza prophylaxis"}]},"trialDetails":[{"nctId":"NCT06507813","phase":"PHASE3","title":"Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza","status":"COMPLETED","sponsor":"Jiaxing AnDiCon Biotech Co.,Ltd","startDate":"2024-08-19","conditions":"Influenza Type A, Influenza Type B","enrollment":190},{"nctId":"NCT06161454","phase":"PHASE4","title":"Xofluza-Wearables Feasibility-Study","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-12-14","conditions":"Infection, Coronavirus, Infections, Influenza","enrollment":498},{"nctId":"NCT03969212","phase":"PHASE3","title":"Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-10-10","conditions":"Influenza","enrollment":4138},{"nctId":"NCT06205641","phase":"NA","title":"A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza A","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2024-01","conditions":"Influenza A","enrollment":584},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04141930","phase":"PHASE4","title":"Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-11-01","conditions":"Influenza, Respiratory Viral Infection","enrollment":481},{"nctId":"NCT02949011","phase":"PHASE3","title":"Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications","status":"COMPLETED","sponsor":"Shionogi","startDate":"2017-01-11","conditions":"Influenza","enrollment":2184},{"nctId":"NCT02954354","phase":"PHASE3","title":"A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza","status":"COMPLETED","sponsor":"Shionogi","startDate":"2016-12-08","conditions":"Influenza","enrollment":1436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Baloxavir Marboxil tablets","genericName":"Baloxavir Marboxil tablets","companyName":"Jiaxing AnDiCon Biotech Co.,Ltd","companyId":"jiaxing-andicon-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baloxavir Marboxil tablets are a small molecule inhibitor of the polymerase acidic protein, classified as an INHIBITOR drug class. They are indicated for the treatment of influenza and have been studied in clinical trials for various conditions including infection, coronavirus, and transplant-related infections.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}